ReviewMolecular medicine (Cambridge, Mass.)2026
Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies.
Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer represents a critical global health burden, particularly among women in countries with limited healthcare infrastructure, where it accounts for a substantial proportion of cancer-related morbidity and mortality. It remains highly prevalent in developing regions. Most cervical cancers are squamous cell carcinomas originating from the cervix lining cells, mainly because of chronic infection with high-risk human papillomaviruses (HPV) types. Additionally, the likelihood of infection is enhanced by behaviours include early sexual activity, multiple partners, smoking, and immunosuppression. Topoisomerases, vital enzymes for DNA replication and transcription are crucial for therapeutic intervention in cancer. Inhibitors of Topoisomerase I and II, such as camptothecin derivatives (topotecan, irinotecan) and drugs like etoposide and daunorubicin, have shown effectiveness in treating cancers, including cervical cancer, by stabilizing topoisomerase-DNA complexes and inducing lethal DNA strand breaks. However, traditional treatments like chemotherapy and radiation often have high toxicity and limited survival benefits. The development of new topoisomerase inhibitors with better efficacy and safety is essential. Advances in tumour biology have led to multi targeting drugs that target multiple cancer cells survival pathways, offering a more comprehensive anti-cancer effect. This review explores the application of topoisomerase inhibitors in advanced and recurrent stages of cervical cancer, both as standalone agents and in combination therapies. Combining topoisomerase inhibitors with other treatment options has been used as a strategy to improve therapeutic outcomes. Additionally new therapeutic strategies like nanoformulations, antibody drug conjugates, and biomarker-based therapies lead to effective therapeutic outcomes in cervical cancer treatment. Ongoing research and development in this area are crucial for enhancing cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.